News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2020
-
Dec 28, 2020
Chugai Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for Olaparib in BRCA- Mutated Prostate Cancer
[PDF 297KB] -
Dec 25, 2020
Chugai Obtains Approval for Tecentriq as a Monotherapy for Chemotherapy-Naïve PD-L1-Positive Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer (NSCLC)
[PDF 232KB] -
Dec 25, 2020
Chugai’s Hemlibra Wins the MHLW Minister's Award at the Fourth Japan Medical Research and Development Grand Prize
[PDF 196KB] -
Dec 23, 2020
The Launch of Chugai’s New TV Commercial Featuring Erika Toda “Personalize My Healthcare, Please.”
[PDF 603KB] -
Dec 18, 2020
Chugai's Osteoporosis Agent Edirol Obtains Regulatory Approval in China
[PDF 195KB] -
Dec 10, 2020
Chugai in-licenses Antibody Cocktail for COVID-19 from Roche
[PDF 282KB] -
Dec 09, 2020
Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)
[PDF 330KB] -
Nov 27, 2020
Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules
[PDF 117KB] -
Nov 24, 2020
Chugai and DeNA Jointly Launch “Ring Again,” a Rheumatoid Arthritis Disease Awareness Project
[PDF 84KB] -
Nov 19, 2020
Chugai Receives the Best IR Award
[PDF 231KB] -
Nov 17, 2020
Chugai Selected for the First Time in the “DJSI World,” a Global ESG Investment Index
[PDF 279KB] -
Nov 17, 2020
Personnel Changes
[PDF 182KB] -
Nov 05, 2020
Chugai Contributes Fourteen Thousand Tons of CO2 Emission Reduction Credits to Tokyo Metropolitan Government
[PDF 205KB] -
Oct 29, 2020
Results from the Investigator-Initiated Phase I Study of RAF/MEK Inhibitor, CKI27 Published in the Lancet Oncology Online
[PDF 365KB] -
Oct 28, 2020
Contribution of Para-transit Vehicles to Welfare Services
[PDF 401KB] -
Oct 22, 2020
Chugai Announces 2020 3rd Quarter Results
[PDF 556KB] -
Oct 21, 2020
Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Novo Nordisk
[PDF 282KB] -
Oct 19, 2020
Chugai and Welby Launch a Treatment Support Personal Health Record Service for Cancer Patients to Promote Proper Use of Tecentriq
[PDF 870KB] -
Oct 15, 2020
Chugai Files a New Drug Application for Risdiplam as the First Oral Drug for Spinal Muscular Atrophy in Japan
[PDF 240KB] -
Oct 15, 2020
F. Hoffmann-La Roche Announces Third Quarter Sales 2020
[PDF 107KB] -
Oct 06, 2020
Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with argenx
[PDF 210KB] -
Oct 02, 2020
Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for Pemigatinib for Patients with FGFR2 Fusion Positive Locally Advanced or Metastatic Cholangiocarcinoma
[PDF 285KB] -
Oct 02, 2020
Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Larotrectinib for TRK Fusion Cancer
[PDF 312KB] -
Sep 25, 2020
Chugai Obtains Approval for Additional Indication of Tecentriq and Avastin as the First Cancer Immunotherapy for Unresectable Hepatocellular Carcinoma
[PDF 331KB] -
Sep 18, 2020
Roche Announces Results of EMPACTA Study for Chugai’s Actemra for the Treatment of COVID-19
[PDF 187KB] -
Sep 10, 2020
New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)
[PDF 200KB] -
Sep 10, 2020
Chugai and Takeda to Join a Clinical Collaboration for Global Phase III Studies for the Combination Therapy with Multiple Tumor Types in Japan
[PDF 299KB] -
Sep 09, 2020
Chugai and NTT DATA Complete Demonstration of AI-based Clinical Trial Efficiency Solution.
-- Support for Clinical Trial- Documentation and Seamless Data Integration into the Subsequent Process -- [PDF 161KB] -
Sep 07, 2020
Online Disease Awareness Activity for Better Understanding Breast Cancer at TOKYO GIRLS COLLECTION
-- A bottom-up project based on an employee’s idea to achieve SDGs -- [PDF 525KB] -
Sep 01, 2020
Chugai Introduces LINE WORKS by WORKS MOBILE Japan for 2,400 Employees including Medical Representatives
[PDF 340KB] -
Aug 26, 2020
Chugai Launches Enspryng (Satralizumab) Subcutaneous Injection 120 mg Syringe, the pH-Dependent Binding Humanized anti-IL-6 Receptor Monoclonal Antibody
[PDF 250KB] -
Aug 26, 2020
Non-Clinical Research Results of Chugai’s Switch Antibody STA551 Published in Cancer Discovery
[PDF 201KB] -
Aug 25, 2020
Chugai Selected as Digital Transformation Stock (DX Stock) 2020
[PDF 264KB] -
Aug 21, 2020
Chugai Obtains Approval for Additional Indication of Kadcyla for Adjuvant Therapy of HER2-Positive Early Breast Cancer
[PDF 287KB] -
Aug 17, 2020
Chugai’s Enspryng (Satralizumab) Receives Regulatory Approval from FDA for Neuromyelitis Optica Spectrum Disorder
[PDF 248KB] -
Aug 05, 2020
Chugai Continues to be Listed for All ESG Indices Selected by GPIF
[PDF 196KB] -
Jul 29, 2020
Chugai Provides an Update on Phase III COVACTA Study of Actemra in Hospitalized Patients with Severe COVID-19 Associated Pneumonia
[PDF 305KB] -
Jul 29, 2020
Roche Announces an Update on COVACTA Study for Chugai’s Actemra for the Treatment of COVID-19
[PDF 187KB] -
Jul 27, 2020
Chugai Announces 2020 Half Year Results
[PDF 824KB] -
Jul 27, 2020
Organizational and Personnel Changes
Chugai Proceeds Structural Reforms of Corporate Functions
[PDF 234KB] -
Jul 27, 2020
F. Hoffmann-La Roche Announces Half Year Results 2020
[PDF 112KB] -
Jul 22, 2020
Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology
[PDF 196KB] -
Jul 20, 2020
Chugai Announces New Partnership with City Cancer Challenge Foundation to Enhance the Quality of Patient-Centered Cancer Care in Yangon
[PDF 197KB] -
Jul 15, 2020
Chugai and Nara Medical University Jointly Win the 4th Japan Bioindustry Award for Discovery and Development of Hemlibra for the Treatment of Hemophilia A
[PDF 200KB] -
Jul 15, 2020
Relief Efforts Support for July 2020 Rain Disaster Victims
[PDF 186KB] -
Jul 13, 2020
New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A
[PDF 293KB] -
Jul 13, 2020
Chugai Provides Update on the Phase III IMagyn050 study of Tecentriq in Combination with Chemotherapy and Avastin as a Treatment of Newly-Diagnosed Ovarian Cancer
[PDF 281KB] -
Jul 09, 2020
Results of Maruho’s Phase III Study with Chugai’s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Online
[PDF 192KB] -
Jun 30, 2020
Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
[PDF 206KB] -
Jun 29, 2020
Chugai’s Enspryng (Satraliazumab) Subcutaneous Injection 120 mg Syringe Approved in Japan for Neuromyelitis Optica Spectrum Disorder
[PDF 249KB] -
Jun 19, 2020
Phase III IPATential150 Study Evaluating Ipatasertib in Combination with Abiraterone and Prednisone/Prednisolone in Patients with Metastatic Castration-Resistant Prostate Cancer Meets One of Its Co-Primary Endpoint
[PDF 201KB] -
Jun 18, 2020
Tecentriq in combination with chemotherapy meets primary endpoint, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
[PDF 286KB] -
Jun 05, 2020
Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lynparza for Metastatic Castration-Resistant Prostate Cancer with HRR-Related Gene Alterations
[PDF 289KB] -
May 29, 2020
Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules against Sawai and Nichi-Iko
[PDF 159KB] -
May 29, 2020
Chugai Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Novartis’ MET inhibitor, Capmatinib for Non-Small Cell Lung Cancer with MET exon 14 Skipping Alterations
[PDF 298KB] -
May 29, 2020
Chugai and FRONTEO Enter into a License Agreement for AI-based Drug Discovery Support System
[PDF 250KB] -
May 29, 2020
Updated Data of Overall Survival and Safety from the ALEX Study for Chugai's Alecensa Presented at the 2020 American Society of Clinical Oncology (ASCO)
[PDF 236KB] -
May 28, 2020
Chugai Starts Online Distribution of a Voice Drama Program “Katarisiennes” by ex-Takarasiennes to Encourage People in Novel Coronavirus Outbreak
[PDF 303KB] -
May 22, 2020
New Longer-Term Safety Data of Chugai’s Satralizumab in Adults and Adolescents with Neuromyelitis Optica Spectrum Disorder Presented at EAN
[PDF 269KB] -
May 21, 2020
Support for Control of Novel Coronavirus in Japan
[PDF 323KB] -
May 15, 2020
Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Eli Lilly and Company
[PDF 281KB] -
May 08, 2020
Chugai and A*STAR Begin Joint Research on a Therapeutic Antibody to Fight COVID-19
[PDF 315KB] -
Apr 24, 2020
Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology
[PDF 214KB] -
Apr 24, 2020
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 115KB] -
Apr 23, 2020
Chugai Announces 2020 1st Quarter Results
[PDF 762KB] -
Apr 22, 2020
F. Hoffmann-La Roche Announces First Quarter Sales 2020
[PDF 107KB] -
Apr 15, 2020
Chugai Conducts Disease Awareness Activities for Better Understanding of Hemophilia in Supporting the World Hemophilia Day
[PDF 290KB] -
Apr 09, 2020
Chugai Calls for the Importance of Cervical Cancer Screening on Uterus Day to Increase Screening Rate
[PDF 205KB] -
Apr 08, 2020
Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan
[PDF 193KB] -
Mar 31, 2020
Chugai Announces CHUGAI DIGITAL VISION 2030 to Accelerate Digital Transformation
[PDF 324KB] -
Mar 31, 2020
Chugai Files for FoundationOne Liquid CDx Aiming to Provide Blood-based Comprehensive Genomic Profiling for Solid Tumors
[PDF 287KB] -
Mar 30, 2020
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 148KB] -
Mar 24, 2020
Genentech Announces FDA approval of Clinical Trial for Chugai’s Actemra for COVID-19 Pneumonia
[PDF 354KB] -
Mar 23, 2020
Chugai Files Patent Infringement Lawsuit against Fresenius Kabi in the U.S.
[PDF 108KB] -
Mar 19, 2020
Roche Announces the Initiation of a Clinical Study of Chugai’s Actemra for the Treatment of COVID-19
[PDF 188KB] -
Mar 17, 2020
Chugai Selected as 2019 Tokyo Sports Promotion Model Company
[PDF 191KB] -
Mar 13, 2020
Chugai Orgazanizes a Workshop on Multidisciplinary Team Care in Cambodia
- To provide advanced and sustainable patient-centric healthcare - [PDF 427KB] -
Feb 21, 2020
Chugai Obtains Approval for Additional Indication of Alecensa for Recurrent or Refractory ALK Fusion Gene-Positive Anaplastic Large Cell Lymphoma
[PDF 349KB] -
Feb 21, 2020
Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer
[PDF 288KB] -
Feb 21, 2020
Anti-CD20 Monoclonal Antibody “Rituxan®,” Approved for Additional Indication of Acquired Thrombotic Thrombocytopenic Purpura
[PDF 80KB] -
Feb 20, 2020
Results of Phase II Study with Chugai’s Nemolizumab for Prurigo Nodularis Published in the New England Journal of Medicine Online
[PDF 325KB] -
Feb 17, 2020
Chugai Receives Orphan Drug Designation for RG6042 in Huntington's Disease from the MHLW
[PDF 373KB] -
Feb 17, 2020
Changes to Marketing Arrangements of the SGLT2 Inhibitor Tofogliflozin Hydrate in Japan
[PDF 160KB] -
Feb 14, 2020
Chugai Files for Additional Indications of Tecentriq and Avastin for the Treatment of Unresectable Hepatocellular Carcinoma
[PDF 241KB] -
Feb 13, 2020
Foundation Medicine and Chugai Announce Partnership with National Cancer Center for the Use of FoundationOne® Liquid in the Third Stage of SCRUM-Japan
[PDF 168KB] -
Feb 13, 2020
Polatuzumab Vedotin Achieved Primary Endpoint in the Japanese Phase II study for Relapsed or Refractory Diffuse Large B-cell Lymphoma
[PDF 210KB] -
Feb 12, 2020
Chugai Wins Second Prize for the Second Consecutive Year in the 22nd NIKKEI Annual Report Awards
- First time to win both Nikkei and WICI Japan Awards for Integrated Reporting - [PDF 215KB] -
Feb 12, 2020
Chugai Joins the Consortium of Companies Promoting Anti-Smoking Efforts
[PDF 280KB] -
Feb 07, 2020
Chugai Supports National Cancer Center Japan for an Investigator-Initiated Clinical Study Based on Patient-Requested Therapy System
[PDF 195KB] -
Feb 07, 2020
Support for Control of Novel Coronavirus
[PDF 274KB] -
Feb 04, 2020
Chugai Supports Statement of Japan Climate Initiative and Recommendations of the Task Force on Climate-related Financial Disclosures
[PDF 194KB] -
Jan 30, 2020
Chugai Announces 2019 Full Year Results and Forecasts for 2020
[PDF 443KB] -
Jan 30, 2020
Notice of Distribution of Retained Earnings
[PDF 179KB] -
Jan 30, 2020
Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year
[PDF 129KB] -
Jan 30, 2020
Organizational and Personnel Changes
[PDF 427KB] -
Jan 30, 2020
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2019
[PDF 107KB] -
Jan 28, 2020
Notice Concerning Execution of Settlement Agreement on Arbitration against Chugai
[PDF 65KB] -
Jan 23, 2020
Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in People with Type 1 Spinal Muscular Atrophy (SMA)
[PDF 197KB] -
Jan 21, 2020
Notice of Stock Split and Partial Amendment to the Articles of Incorporation
[PDF 88KB] -
Jan 09, 2020
Chugai Announces Global Licensing Agreement with Verastem Oncology for RAF/MEK Inhibitor CKI27
[PDF 275KB]
